These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 30283995)

  • 1. Can urinary biomarkers replace cystoscopy?
    Maas M; Bedke J; Stenzl A; Todenhöfer T
    World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary markers in the everyday diagnosis of bladder cancer.
    Dal Moro F; Valotto C; Guttilla A; Zattoni F
    Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
    Zuiverloon TCM; de Jong FC; Theodorescu D
    Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions.
    Ng K; Stenzl A; Sharma A; Vasdev N
    Urol Oncol; 2021 Jan; 39(1):41-51. PubMed ID: 32919875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine markers for bladder cancer surveillance: a systematic review.
    van Rhijn BW; van der Poel HG; van der Kwast TH
    Eur Urol; 2005 Jun; 47(6):736-48. PubMed ID: 15925067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Use and Promise of Urinary Markers for Urothelial Cancer.
    Tabayoyong W; Kamat AM
    Curr Urol Rep; 2018 Oct; 19(12):96. PubMed ID: 30328534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer.
    Maas M; Walz S; Stühler V; Aufderklamm S; Rausch S; Bedke J; Stenzl A; Todenhöfer T
    Expert Rev Mol Diagn; 2018 May; 18(5):443-455. PubMed ID: 29707982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-invasive urinary diagnosis of bladder cancer. What do we know?].
    Kausch I; Böhle A
    Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urine cytology and urine markers. Significance for clinical practice].
    Tritschler S; Zaak D; Knuechel R; Stief CG
    Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder cancer. II. Molecular aspects and diagnosis.
    Kausch I; Böhle A
    Eur Urol; 2001 May; 39(5):498-506. PubMed ID: 11464029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
    Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR
    Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.
    Lotan Y; Black PC; Caba L; Chang SS; Cookson MS; Daneshmand S; Kamat AM; McKiernan JM; Pruthi RS; Ritch CR; Steinberg GD; Svatek RS; Zwarthoff EC
    Eur Urol Oncol; 2018 Aug; 1(3):223-230. PubMed ID: 31102625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 18. Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review.
    Agreda Castañeda F; Raventós Busquets CX; Morote Robles J
    Actas Urol Esp (Engl Ed); 2019 Oct; 43(8):404-413. PubMed ID: 31097210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
    Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
    BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles.
    Oeyen E; Hoekx L; De Wachter S; Baldewijns M; Ameye F; Mertens I
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.